Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?: Editorials

Journal of the National Cancer Institute

Volumn 90, Issue 18, 1998, Pages 1320-1321

  Clark, G M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MELPHALAN; METHOTREXATE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; DOSE RESPONSE; EDITORIAL; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; ONCOGENE NEU; PROGNOSIS;

EID: 0032538006     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.18.1320     Document Type: Editorial

References (10)